Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Head and Neck Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 76 articles:
HTML format



Single Articles


    June 2022
  1. ZHANG Y, Chen L, Hu GQ, Zhang N, et al
    Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2022 Jun 16:JCO2200327. doi: 10.1200/JCO.22.00327.
    PubMed     Abstract available


  2. NORONHA V, Patil VM, Menon N, Prabhash K, et al
    Change in Pattern of Failure in Head and Neck Cancer.
    J Clin Oncol. 2022 Jun 16:JCO2200598. doi: 10.1200/JCO.22.00598.
    PubMed    


  3. BROSE MS, Pryma DA, Newbold KL
    Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
    J Clin Oncol. 2022;40:1847-1849.
    PubMed    


  4. HO AL, Dedecjus M, Wirth LJ, Tuttle RM, et al
    Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
    J Clin Oncol. 2022;40:1870-1878.
    PubMed     Abstract available


    May 2022
  5. GUPTA T, Maheshwari G, Kannan S, Nair S, et al
    Should Sentinel Lymph Node Biopsy Be Considered the New Standard of Care for Early-Stage Clinically Node-Negative Oral Squamous Cell Carcinoma?
    J Clin Oncol. 2022;40:1706-1709.
    PubMed    


  6. MCDONALD AM, Lindeman B, Bahl D
    Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance.
    J Clin Oncol. 2022;40:1396-1399.
    PubMed    


  7. PASQUAL E, Schonfeld S, Morton LM, Villoing D, et al
    Association Between Radioactive Iodine Treatment for Pediatric and Young Adulthood Differentiated Thyroid Cancer and Risk of Second Primary Malignancies.
    J Clin Oncol. 2022;40:1439-1449.
    PubMed     Abstract available


    April 2022
  8. HAYES DN, Gleysteen JP, Schwartz DL
    For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting.
    J Clin Oncol. 2022 Apr 21:JCO2200274. doi: 10.1200/JCO.22.00274.
    PubMed    


  9. SHEN L, Kato K, Kim SB, Ajani JA, et al
    Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2022 Apr 20:JCO2101926. doi: 10.1200/JCO.21.01926.
    PubMed     Abstract available


  10. FRANCO AT, Ricarte-Filho JC, Isaza A, Jones Z, et al
    Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers.
    J Clin Oncol. 2022;40:1081-1090.
    PubMed     Abstract available


  11. FERRIS RL, Burtness B, Flamand Y
    Reply to A.S. Garden.
    J Clin Oncol. 2022;40:1133-1134.
    PubMed    


  12. FAGIN JA
    Age of Onset of Receptor Tyrosine Kinase Fusions Drives Distinct Biologic Outcomes in Thyroid Cancer.
    J Clin Oncol. 2022;40:1124-1126.
    PubMed    


    March 2022
  13. BURTNESS B, Rischin D, Greil R, Soulieres D, et al
    Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
    J Clin Oncol. 2022 Mar 25:JCO2102198. doi: 10.1200/JCO.21.02198.
    PubMed     Abstract available


  14. MOWERY YM, Salama JK
    Interpreting ORATOR: Lessons Learned From a Randomized Comparison of Primary Surgical and Radiation Approaches for Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:814-817.
    PubMed    


  15. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial.
    J Clin Oncol. 2022;40:866-875.
    PubMed     Abstract available


  16. KIYOTA N, Tahara M, Mizusawa J, Kodaira T, et al
    Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 1:JCO2101293. doi: 10.1200/JCO.21.01293.
    PubMed     Abstract available


    February 2022
  17. NG WT, Chua MLK, Lee AWM
    Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: Quo Vadis?
    J Clin Oncol. 2022 Feb 25:JCO2200099. doi: 10.1200/JCO.22.00099.
    PubMed    


  18. GARDEN AS
    Transoral Surgery With Neck Dissection Is an Excellent Treatment for the Appropriately Selected Patient With Early-Stage Oropharyngeal Cancer.
    J Clin Oncol. 2022 Feb 16:JCO2102630. doi: 10.1200/JCO.21.02630.
    PubMed    


  19. ZHAO JJ, Yap DWT, Chan YH, Tan BKJ, et al
    Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    J Clin Oncol. 2022;40:392-402.
    PubMed     Abstract available


    January 2022
  20. CHAUKAR D, Prabash K, Rane P, Patil VM, et al
    Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.
    J Clin Oncol. 2022;40:272-281.
    PubMed     Abstract available


  21. MCDOWELL L, Magarey MJR, Rischin D
    Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer.
    J Clin Oncol. 2022;40:114-117.
    PubMed    


  22. FERRIS RL, Flamand Y, Weinstein GS, Li S, et al
    Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    J Clin Oncol. 2022;40:138-149.
    PubMed     Abstract available


  23. LI XY, Luo DH, Guo L, Mo HY, et al
    Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
    J Clin Oncol. 2022 Jan 6:JCO2101467. doi: 10.1200/JCO.21.01467.
    PubMed     Abstract available


    December 2021
  24. HO AL
    Androgen Receptor Pathway in Salivary Gland Cancer.
    J Clin Oncol. 2021;39:4069-4072.
    PubMed    


  25. LOCATI LD, Cavalieri S, Bergamini C, Resteghini C, et al
    Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial.
    J Clin Oncol. 2021;39:4061-4068.
    PubMed     Abstract available


  26. KEILTY D, Khandwala M, Liu ZA, Papaioannou V, et al
    Hearing Loss After Radiation and Chemotherapy for CNS and Head-and-Neck Tumors in Children.
    J Clin Oncol. 2021;39:3813-3821.
    PubMed     Abstract available


    November 2021
  27. XU B, Fuchs TL, Ahmadi S, Alghamdi M, et al
    International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
    J Clin Oncol. 2021 Nov 3:JCO2101329. doi: 10.1200/JCO.21.01329.
    PubMed     Abstract available


  28. ADENIS A, Kulkarni AS, Girotto GC, de la Fouchardiere C, et al
    Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
    J Clin Oncol. 2021 Nov 3:JCO2100601. doi: 10.1200/JCO.21.00601.
    PubMed     Abstract available


    October 2021
  29. SHAH MA, Hofstetter WL, Kennedy EB
    Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021;39:3182-3184.
    PubMed     Abstract available


    September 2021
  30. POTTGEN C, Nestle U, Hocht S, Stuschke M, et al
    Interactions Between Dose and Volume in Chemoradiotherapy of Esophageal Cancer.
    J Clin Oncol. 2021 Sep 23:JCO2101579. doi: 10.1200/JCO.21.01579.
    PubMed    


    August 2021
  31. KALRA B, Sinha S, Laskar SG
    De-Escalation in HPV: Near Yet Elusive.
    J Clin Oncol. 2021;39:2733-2734.
    PubMed    


  32. CMELAK AJ, Ferris RL, Chen AM, Seiwert T, et al
    Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
    J Clin Oncol. 2021;39:2732-2733.
    PubMed    


  33. HONG S, Zhang Y, Yu G, Peng P, et al
    Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
    J Clin Oncol. 2021 Aug 11:JCO2100396. doi: 10.1200/JCO.21.00396.
    PubMed     Abstract available


  34. LI B, Chen H
    The Best Surgery Should Be Applied for Locally Advanced Esophageal Cancer.
    J Clin Oncol. 2021 Aug 2:JCO2101340. doi: 10.1200/JCO.21.01340.
    PubMed    


    June 2021
  35. HULSHOF MCCM, Geijsen ED, Rozema T, Oppedijk V, et al
    Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    J Clin Oncol. 2021 Jun 8:JCO2003697. doi: 10.1200/JCO.20.03697.
    PubMed     Abstract available


  36. GOODMAN KA, Ou FS, Hall NC, Bekaii-Saab T, et al
    Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003611. doi: 10.1200/JCO.20.03611.
    PubMed     Abstract available


    May 2021
  37. HIRSHOREN N, Weinberger JM
    Surgical Perspective on Sentinel Node Biopsy for Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2021;39:1598-1599.
    PubMed    


  38. LIU MA, Hsu WT, Johnstone C, Chang A, et al
    Interpreting the Clinical Utility of Early Interdisciplinary Supportive Care for Untreated Metastatic Esophageal Cancer.
    J Clin Oncol. 2021 May 7:JCO2100122. doi: 10.1200/JCO.21.00122.
    PubMed    


  39. YOKOYAMA K, Ishiki H
    Questions Regarding Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer.
    J Clin Oncol. 2021 May 5:JCO2100456. doi: 10.1200/JCO.21.00456.
    PubMed    


    April 2021
  40. EYCK BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, et al
    Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.
    J Clin Oncol. 2021 Apr 23:JCO2003614. doi: 10.1200/JCO.20.03614.
    PubMed     Abstract available


  41. PEARSON AT, Vokes EE
    Is This the Dawn of Precision Oncology in Head and Neck Cancer?
    J Clin Oncol. 2021 Apr 20:JCO2100569. doi: 10.1200/JCO.21.00569.
    PubMed    


  42. HASEGAWA Y, Tsukahara K, Yoshimoto S, Miura K, et al
    Neck Dissections Based on Sentinel Lymph Node Navigation Versus Elective Neck Dissections in Early Oral Cancers: A Randomized, Multicenter, and Noninferiority Trial.
    J Clin Oncol. 2021 Apr 20:JCO2003637. doi: 10.1200/JCO.20.03637.
    PubMed     Abstract available


  43. MINAMI H, Kiyota N, Omori T
    Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?
    J Clin Oncol. 2021 Apr 12:JCO2003262. doi: 10.1200/JCO.20.03262.
    PubMed    


    March 2021
  44. HO AL, Brana I, Haddad R, Bauman J, et al
    Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
    J Clin Oncol. 2021 Mar 22:JCO2002903. doi: 10.1200/JCO.20.02903.
    PubMed     Abstract available


  45. CHUNDURY A, Kim S
    Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
    J Clin Oncol. 2021;39:947-949.
    PubMed    


  46. YOM SS, Torres-Saavedra P, Caudell JJ, Waldron JN, et al
    Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    J Clin Oncol. 2021;39:956-965.
    PubMed     Abstract available


  47. CHAKRABARTI D, Akhtar N, Rajan S, Qayoom S, et al
    What Is the Acceptable Noninferiority Limit for Nodal Recurrences When Ascertaining Sentinel Lymph Node Biopsy as an Alternative to Neck Dissection for Early Oral and Oropharyngeal Cancers?
    J Clin Oncol. 2021 Mar 11:JCO2003439. doi: 10.1200/JCO.20.03439.
    PubMed    


    January 2021
  48. WANG FH, Wei XL, Feng J, Li Q, et al
    Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    J Clin Oncol. 2021 Jan 25:JCO2002712. doi: 10.1200/JCO.20.02712.
    PubMed     Abstract available


  49. CHEUNG LC, Ramadas K, Muwonge R, Katki HA, et al
    Risk-Based Selection of Individuals for Oral Cancer Screening.
    J Clin Oncol. 2021 Jan 15:JCO2002855. doi: 10.1200/JCO.20.02855.
    PubMed     Abstract available


  50. LU Z, Fang Y, Liu C, Zhang X, et al
    Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2021 Jan 8:JCO2001254. doi: 10.1200/JCO.20.01254.
    PubMed     Abstract available


  51. NOEL CW, Sutradhar R, Zhao H, Delibasic V, et al
    Patient-Reported Symptom Burden as a Predictor of Emergency Department Use and Unplanned Hospitalization in Head and Neck Cancer: A Longitudinal Population-Based Study.
    J Clin Oncol. 2021 Jan 6:JCO2001845. doi: 10.1200/JCO.20.01845.
    PubMed     Abstract available


  52. CHEN YP, Ismaila N, Chua MLK, Colevas AD, et al
    Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.
    J Clin Oncol. 2021 Jan 6:JCO2003237. doi: 10.1200/JCO.20.03237.
    PubMed     Abstract available


  53. GEBRE-MEDHIN M, Brun E, Engstrom P, Haugen Cange H, et al
    ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.
    J Clin Oncol. 2021;39:38-47.
    PubMed     Abstract available


  54. SEIWERT TY, Kiess AP
    Time to Debunk an Urban Myth? The "Abscopal Effect" With Radiation and Anti-PD-1.
    J Clin Oncol. 2021;39:1-3.
    PubMed    


  55. WIJNHOVEN BPL, Lagarde SM
    Minimally Invasive Esophagectomy: Time to Reflect on Contemporary Outcomes.
    J Clin Oncol. 2021;39:90-91.
    PubMed    


  56. NUYTENS F, Voron T, Piessen G
    Hybrid Minimally Invasive Esophagectomy to the Rescue: A Valid Alternative for Phased Dissemination of TMIE?
    J Clin Oncol. 2021;39:91-92.
    PubMed    


    December 2020
  57. JHAWAR SR, Bonomi M, Harari PM
    Treating Advanced Head and Neck Cancer When Cisplatin Is Not an Option.
    J Clin Oncol. 2020 Dec 4:JCO2002720. doi: 10.1200/JCO.20.02720.
    PubMed     Abstract available


  58. LAI SY, Ferris RL
    Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer.
    J Clin Oncol. 2020;38:3983-3986.
    PubMed    


  59. GARREL R, Poissonnet G, Moya Plana A, Fakhry N, et al
    Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:4010-4018.
    PubMed     Abstract available


    October 2020
  60. KOJIMA T, Shah MA, Muro K, Francois E, et al
    Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
    J Clin Oncol. 2020 Oct 7:JCO2001888. doi: 10.1200/JCO.20.01888.
    PubMed     Abstract available


    August 2020
  61. MCBRIDE S, Sherman E, Tsai CJ, Baxi S, et al
    Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
    J Clin Oncol. 2020 Aug 21:JCO2000290. doi: 10.1200/JCO.20.00290.
    PubMed     Abstract available


  62. KREISSL MC, Bastholt L, Elisei R, Haddad R, et al
    Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
    J Clin Oncol. 2020;38:2773-2781.
    PubMed     Abstract available


  63. SHAH MA, Kennedy EB, Catenacci DV, Deighton DC, et al
    Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.
    J Clin Oncol. 2020;38:2677-2694.
    PubMed     Abstract available


  64. MAGHAMI E, Ismaila N, Alvarez A, Chernock R, et al
    Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline.
    J Clin Oncol. 2020;38:2570-2596.
    PubMed     Abstract available


    July 2020
  65. SIMONE CB 2ND
    First Randomized Trial Supporting the Use of Proton Over Photon Chemoradiotherapy in Esophageal Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2001405. doi: 10.1200/JCO.20.01405.
    PubMed    


  66. CATENACCI DVT, Rasco D, Lee J, Rha SY, et al
    Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma.
    J Clin Oncol. 2020;38:2418-2426.
    PubMed     Abstract available


    June 2020
  67. LIM AM, Solomon BJ
    Immunotherapy for Anaplastic Thyroid Carcinoma.
    J Clin Oncol. 2020 Jun 18:JCO2001437. doi: 10.1200/JCO.20.01437.
    PubMed    


  68. MAKIYAMA A, Sukawa Y, Kashiwada T, Kawada J, et al
    Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
    J Clin Oncol. 2020;38:1919-1927.
    PubMed     Abstract available


  69. MEHANNA H, Rischin D, Wong SJ, Gregoire V, et al
    De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
    J Clin Oncol. 2020 Jun 4:JCO2000056. doi: 10.1200/JCO.20.00056.
    PubMed     Abstract available


  70. POWELL SF, Gold KA, Gitau MM, Sumey CJ, et al
    Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
    J Clin Oncol. 2020 Jun 1:JCO1903156. doi: 10.1200/JCO.19.03156.
    PubMed     Abstract available


  71. KANN BH, Payabvash S, Aneja S
    Reply to A.B. Simon et al.
    J Clin Oncol. 2020;38:1869-1870.
    PubMed    


  72. SIMON AB, Vitzthum LK, Mell LK
    Challenge of Directly Comparing Imaging-Based Diagnoses Made by Machine Learning Algorithms With Those Made by Human Clinicians.
    J Clin Oncol. 2020;38:1868-1869.
    PubMed    


    May 2020
  73. CAPDEVILA J, Wirth LJ, Ernst T, Ponce Aix S, et al
    PD-1 Blockade in Anaplastic Thyroid Carcinoma.
    J Clin Oncol. 2020 May 4:JCO1902727. doi: 10.1200/JCO.19.02727.
    PubMed     Abstract available


    April 2020
  74. CHERA BS, Kumar S, Shen C, Amdur R, et al
    Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
    J Clin Oncol. 2020;38:1050-1058.
    PubMed     Abstract available


    February 2020
  75. IQBAL S, McDonough S, Lenz HJ, Ilson D, et al
    Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of ERCC1: SWOG S1201.
    J Clin Oncol. 2020;38:472-479.
    PubMed     Abstract available


  76. STROES CI, Schokker S, Creemers A, Molenaar RJ, et al
    Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
    J Clin Oncol. 2020;38:462-471.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: